BioX­cel scores an­oth­er win with re­for­mu­lat­ed Pfiz­er seda­tive, this time in an Alzheimer's symp­tom

Less than six months af­ter re­port­ing pos­i­tive Phase III re­sults for its lead pro­gram in treat­ing ag­i­ta­tion re­lat­ed to schiz­o­phre­nia and bipo­lar dis­or­der, small AI …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER